Related Experiment Video

Updated: Aug 27, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile

Meredith B Oliver1, Byron P Vaughn2

  • 1M Health Fairview, Masonic Children's Hospital, Minneapolis, MN, USA.

Clinical Pharmacology : Advances and Applications
|September 30, 2022
PubMed

Insights

Fidaxomicin offers a safe and effective treatment for pediatric Clostridioides difficile infection (CDI). This minimally absorbed antibiotic shows similar efficacy to vancomycin but with a reduced risk of CDI recurrence.

Area of Science:

  • Infectious Diseases
  • Pediatric Pharmacology
  • Microbiology

Background:

  • Clostridioides difficile infection (CDI) is a significant health concern in both hospital and community settings.
  • Fidaxomicin presents a unique profile among antibiotics due to its minimal absorption and narrow spectrum, making it a potential candidate for pediatric use.
  • Balancing safety and efficacy is crucial when selecting treatments for pediatric CDI.

Purpose of the Study:

  • To review the existing clinical evidence regarding the safety and efficacy of fidaxomicin for treating pediatric CDI.
  • To assess fidaxomicin's suitability as a therapeutic option for children diagnosed with CDI.

Main Methods:

  • A structured literature search was conducted to gather relevant clinical data on fidaxomicin in pediatric CDI.
  • The review focused on studies evaluating both the safety and efficacy endpoints of fidaxomicin treatment.

Main Results:

  • Fidaxomicin demonstrated comparable effectiveness to oral vancomycin in treating pediatric CDI.
  • A notable finding was the lower rate of recurrent CDI observed with fidaxomicin compared to vancomycin.
  • No significant safety concerns were identified with the use of fidaxomicin in the pediatric population.

Conclusions:

  • Fidaxomicin is established as a safe and effective treatment choice for pediatric Clostridioides difficile infection.
  • Its favorable profile, including reduced recurrence rates, positions fidaxomicin as a valuable option for managing CDI in children.

Keywords:
Dificidcolitisdiarrheamicrobiota

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

39.0K

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
270
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
255
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
193
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
174
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
190